Viral Vector Coated with Polypeptides for T Cell Re-Engagement

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer immunotherapy struggles to optimally utilize the interplay between CD4+ and CD8+ T cell populations, limiting the effectiveness of anti-tumor immune responses.

Innovation Solution

A viral vector with modified viral capsid or envelope, coated with polypeptides including pathogen-specific antigens and anti-tumor peptides, is used to re-engage pre-existing CD4+ memory T cells, enhancing the anti-tumor CD8+ T cell response.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional cancer immunotherapy is used, then anti-tumor CD8+ T cell response is generated, but the effectiveness is limited due to inability to optimally utilize CD4+ T cell interplay

Engineering Contradiction:

Improveanti-tumor immune response effectivenessVSAvoidutilization of CD4+ and CD8+ T cell interplay

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent combines pathogen-specific antigens and anti-tumor antigens on a single viral vector platform, enabling simultaneous engagement of both CD4+ memory T cells (through pathogen antigens) and anti-tumor CD8+ T cells (through tumor antigens), thereby merging two immune responses into one therapeutic intervention

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The viral vector acts as an intermediary carrier that delivers both pathogen-specific and anti-tumor antigens to the immune system, facilitating the interaction between pre-existing CD4+ memory T cells and the generation of anti-tumor CD8+ T cell responses

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If pathogen-specific CD4+ memory T cells are re-engaged, then anti-tumor CD8+ T cell response is enhanced, but requires pre-existing immunity against specific pathogens

Engineering Contradiction:

Improveanti-tumor immune response effectivenessVSAvoidapplicability to different patient populations

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The viral vector is designed with multi-functionality, serving both as a carrier for antigen delivery and as a means to engage pre-existing immune memory, making it applicable across different patient populations by selecting appropriate pathogen antigens based on vaccination history

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Reliability

If viral vector is coated with multiple polypeptides, then immune response is enhanced, but manufacturing complexity increases

Engineering Contradiction:

Improveimmune response effectivenessVSAvoidviral vector production

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

Multiple polypeptides (pathogen-specific antigens and anti-tumor antigens) are merged into a single viral vector coating process, simplifying manufacturing by consolidating multiple antigen delivery functions into one platform rather than requiring separate vector preparations

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS12337030B2Viral vector

Publication Date: 2025.06.24 VALO THERAPEUTICS OY

AI summary

The invention concerns a novel viral vector with modified viral capsid or viral envelope; a pharmaceutical composition or immunogenic agent or vaccine comprising same; a target cell transformed or transfected with same; a combination therapeutic comprising same; use of same in treatment of cancer, and a method of treating cancer using same.